

Kindly replace Claims 44, 48, 51, 56 and 62 as follows:

80 F1
E1
44. (Amended) An antitumoral composition comprising at least one recombinant vector comprising sequence encoding at least one immunogenic polypeptide, wherein said polypeptide is a polypeptide naturally having a nonmembrane location and which is modified by inserting a membrane anchoring sequence so as to have a membrane location at the surface of the cells in which it is expressed, wherein said vector is a non-integrative vector and wherein said immunogenic polypeptide is derived from a polypeptide encoded by the E6 or E7 early region of a papillomavirus genome.

E2
48. (Amended) The antitumoral composition according to claim 44, wherein said vector further comprises a sequence encoding at least one polypeptide derived from a late polypeptide of a papillomavirus.

E3
51. (Amended) The antitumoral composition according to claim 50, wherein said compound enhancing the antitumoral effect is an immunostimulator.

80 F4
E4
56. (Amended) A recombinant vector comprising the sequences encoding one or more immunogenic polypeptide(s), wherein at least one of said polypeptides is a polypeptide as defined in claim 44.

62. (Amended) The antitumoral composition according to claim 48, wherein at least one immunogenic polypeptide is such that:

E5
(1) said immunogenic polypeptide has a sequence homologous or identical to that shown in SEQ ID NO: 1 and wherein said recombinant vector further comprises sequence encoding the L1 protein of a papillomavirus and/or the L2 protein of a papillomavirus,

(2) said immunogenic polypeptide has a sequence homologous or identical to that shown in SEQ ID NO: 2, and wherein said recombinant vector further comprises sequence encoding the L1 protein of a papillomavirus and/or the L2 protein of a papillomavirus, or

E 5

(3) said immunogenic polypeptide has a sequence homologous or identical to that shown in SEQ ID NO: 1, an immunogenic polypeptide having a sequence homologous or identical to that shown in SEQ ID NO: 2, and wherein said recombinant vector further comprises sequence encoding the L1 protein of a papillomavirus and/or the L2 protein of a papillomavirus.

Kindly add claims 65-72 as follows:

65. (New) The antitumoral composition according to claim 44, wherein said papillomavirus is selected from the group consisting of HPV-16, HPV-18, HPV-31, HPV-33 and HPV-45.

E 6

66. (New) The antitumoral composition according to claim 53, wherein said poxvirus is MVA.

67. (New) The antitumoral composition according to claim 64, wherein said poxvirus is MVA.

68. (New) The antitumoral composition according to claim 63, wherein said compound which enhances the antitumoral effect is interleukin-2.

Sub F6

69. (New) A method for the treatment of cancer or a tumor in a subject comprising administering an effective amount of the antitumoral composition according to claim 62 to said subject to treat said cancer or tumor in said subject.

70. (New) The method of claim 69, wherein said subject is diagnosed as having cancer of cervix, a low grade cervical dysplasia or a papillomavirus infection.

E6 71 (New) A method for the treatment of cancer or a tumor in a subject comprising administering an effective amount of the viral particle according to claim 57 to said subject to treat said cancer or tumor in said subject.

72. (New) The method of claim 71, wherein said subject is diagnosed as having cancer of cervix, a low grade cervical dysplasia or a papillomavirus infection.
